loader image
Friday, October 17, 2025
72 F
McAllen
- Advertisement -

Nasal Drugs Show Promise for Slowing Parkinson’s Disease Progression in Lab Study

'A remarkable advance' if results can be replicated, Rush researcher says

Translate to Spanish or other 102 languages!

Potential new treatments for Parkinson’s disease developed by researchers at Rush University Medical Center have shown success in slowing progression of the disease in mice.

Mega Doctor News

- Advertisement -

By Rush University Medical Center 

Newswise — Potential new treatments for Parkinson’s disease developed by researchers at Rush University Medical Center have shown success in slowing progression of the disease in mice.

In a study published in Nature Communications, Rush researchers found that two different peptides (chains of amino acids) helped slow the spread of alpha-synuclein, a protein that occurs in abnormal protein deposits called Lewy bodies in the brain. Lewy bodies are hallmarks of Parkinson’s disease, the most common movement disorder affecting about 1.2 million people in the United States and Canada.

- Advertisement -

“Currently, there are no treatments that slow the progression of Parkinson’s disease — they only treat the symptoms,” says Kalipada Pahan, PhD, the Floyd A. Davis Professor of Neurology at Rush University Medical Center, and a research career scientist at the Jesse Brown VA Medical Center, who led the study.

Lewy bodies are also associated with the development of Lewy body dementia and a rare neurological disorder called multiple system atrophy (MSA). “At present, there is also no effective treatment for dementia with Lewy bodies and multiple system atrophy,” Pahan says. “Understanding how these diseases work is important to developing effective drugs that inhibit alpha-synuclein pathology, protect the brain, and stop the progression of Lewy body diseases.”

The lab-developed peptides tested in the study are known as TLR2-interacting domain of Myd88 (TIDM) and NEMO-binding domain (NBD). The drugs, which were delivered through the nose, were found to slow inflammation in the brain and stop the spread of alpha-synuclein in mice with Parkinson’s disease. The treatments also improved the mice’s gait, balance, and other motor functions. “If these results can be replicated in patients, it would be a remarkable advance in the treatment of devastating neurological disorders,” Pahan says.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

2025 DHR Health Fashion Show & Gala Honoring Heroic Patients

The Edinburg Conference Center at Renaissance was filled with emotion, gratitude, and hope on Wednesday, October 15, 2025, as DHR Health hosted its 2025 Fashion Show & Gala Honoring Heroic Patients. The annual event celebrated breast cancer survivors and highlighted the importance of breast reconstruction awareness, education, and innovation in women’s health care.

STHS Children’s Partners with Spirit Halloween for Pre-Halloween Party for Patients

Due to fears related to any pain they may be experiencing, the unknown environment with strange sounds and unfamiliar faces and separation from family and friends, a hospital stay can result in stress and anxiety in children.

HHSC Encourages Preventive Care During Breast Cancer Awareness Month

The Texas Health and Human Services Commission is encouraging preventive care and screenings for women during Breast Cancer Awareness Month in October.

STHS Children’s Children’s Fall Festival, Oct. 24th

South Texas Health System Children’s will host its popular Children’s Fall Festival on Friday, October 24, exactly one week before All Hallows’ Eve.
- Advertisement -
×